Slušaj Communicable podkast

Communicable E62: The 'prose' and cons of the POET trial – early oral antibiotic switch for endocarditis	Communicable	52:15
Communicable E61: We will make you love PK/PD, part 3	Communicable	52:53
Communicable E60: Quarterly catch-up (August 2026 edition)	Communicable	49:12
Communicable E59: 'Ask me anything' – EUCAST and CLSI leadership explain	Communicable	69:25
Communicable E58: Reducing hospital-acquired pneumonia – the HAPPEN trial and how it happened	Communicable	54:27
Communicable E57: We will make you love PK/PD, part 2	Communicable	47:26
Communicable E56: Frequentist vs Bayesian for clinical trial analysis – 99% probability you’ll want to listen to this	Communicable	65:21
Communicable E55: Bonus episode – Bundibugyo ebolavirus outbreak	Communicable	57:23
Communicable E54: ESCMID Global Late Breakers, part 2	Communicable	55:55
Communicable E53: ESCMID Global Late Breakers, part 1	Communicable	60:09
Communicable E52: ESCMID Global Trials, PETER PEN and ASTARTE	Communicable	60:25
A message to listeners, 4 May 2026	Communicable	01:08
Communicable E51: We will make you love PK/PD, part 1	Communicable	47:48
Communicable E50: Quarterly catch-up (April 2026 edition)	Communicable	58:57
Communicable E49: Outbreaks & how to handle them	Communicable	54:47
Communicable E48: International Women's Day - are infections & AMR really different in women?	Communicable	39:24
Communicable E47: Drawing the line - the writing, reach, and limits of guidelines	Communicable	60:09
Communicable E46: Steroids for pneumocystis pneumonia	Communicable	55:14
Communicable E45: Top infectious diseases papers in 2025	Communicable	38:44
Communicable E44: Top clinical microbiology papers in 2025	Communicable	70:53
Communicable E43: Katie's picks	Communicable	47:23
Communicable E42: Should doctors stay at X (Twitter) or leave it?	Communicable	65:03
Communicable E41: Diagnostic stewardship	Communicable	62:07
Communicable E40: AMR in conflict and crisis zones	Communicable	57:24
Communicable E39: Dengue on the rise	Communicable	56:51
Communicable E38: Why do you have to be so complicated? The 2025 IDSA Complicated UTI Guidelines	Communicable	48:13
Communicable E37: 'Peer review is broken'	Communicable	67:02
Communicable E36: Finding BALANCE in antibiotic durations—the BALANCE trial	Communicable	69:33
Communicable E35: From Ebola to COVID-19 — Graham and Kobinger on building vaccines	Communicable	58:13
Communicable E34: WHO's Fungal Priority Pathogens List	Communicable	50:24
Communicable E33: Ethics in infectious diseases	Communicable	36:51
Communicable E32: Fluoroquinolones - to heal or harm?	Communicable	55:56
Communicable E31: Climate change and fungal spread	Communicable	51:53
Communicable E30: WHO's first-ever guideline on meningitis	Communicable	60:57
Communicable E29: Bacterial vaginosis & male partners	Communicable	59:33
Communicable E28: Late-breaker trials at ESCMID Global: Should they change your practice? - part 2	Communicable	47:22
Communicable E27: Late-breaker trials at ESCMID Global: Should they change your practice? - part 1	Communicable	53:38
Communicable E26: SNAP out of it: Rethinking anti-staphylococcal penicillins for S. aureus bacteremia - the SNAP trial PSSA/MSSA results	Communicable	70:50
Communicable E25: The Nightmare Series, part 5 - Measles is back	Communicable	55:27
Communicable E24: The role of medical societies in global health - An interview with ESCMID leadership	Communicable	47:50

Communicable E62: The 'prose' and cons of the POET trial – early oral antibiotic switch for endocarditis

Communicable

52:15

Communicable E61: We will make you love PK/PD, part 3

Communicable

52:53

Communicable E60: Quarterly catch-up (August 2026 edition)

Communicable

49:12

Communicable E59: 'Ask me anything' – EUCAST and CLSI leadership explain

Communicable

69:25